Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Cellophil™ is a platform of novel polymers based on amino-acid groups. The platform polymers show superior biocompatibility and can be loaded with drugs for controlled release. More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Innovative CHEWABLE TABLETS Iron based More
Novel Surgical Clips for Vascular Bypass and Tissue Grafts for Vascular surgery, vascular grafts, sutureless anastomosis and bypass surgery More
DNA-Based Therapeutic Angiogenesis / Protein Therapeutic for Thrombocytopenia / Therapeutic Cancer Vaccine Targeting HER2/neu / Hardy Kiwi Extract for Immune Hypersensitivity More
Multilayered controlled release oral solid pharmaceutical composition in tablet form suitable for oral administration comprising at least two layers containing active material in association with excipients and additives. More
Retractable inhibitors controlled through polypeptide-protein interactions with the flexible peptide bridge that link the two binding fragments may represent an alternative approach to antidote-reversible anticoagulant therapy. More
Compositions and methods of use of A2 adenosine receptor (AR) agonists for treating conditions modulated by A2A and A2B ARs including myocardial ischemia, reperfusion injury, cystic fibrosis, erectile dysfunction, inflammation, restenosis and septic shock More
Related Reports
Market Research Reports provided by reports.innovaro.com
Aug 2008 - 120 pages - $1,040
Jan 2009 - $15,200
Sep 2010 - 412 pages - $1,040
Nov 2010 - 7 pages - $500
Jan 2010 - $15,200
May 2011 - 43 pages - $500
Nov 2010 - 40 pages - $500
Aug 2008 - 352 pages - $2,615
Dec 2010 - 36 pages - $500
May 2011 - 23 pages - $125
Your selection
- Therapeutic target
- Cardiovascular del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Acute coronary syndromes
- Anemia
- Anticoagulants
- Blood clotting
- Blood composition
- Cardiovascular disorder (other)
- Cerebrovascular disorders
- Thrombotic disorders
- Treatments
- Vascular
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us